Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Amid a Big Week for the U.S. Economy, PFE, BP, EL Report
02:15pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Ahead of today's opening bell, we're in the green again, but only dipping a toe in the water just yet.
Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down
04:29pm, Friday, 29'th Apr 2022 Zacks Investment Research
Bristol-Myers (BMY) earnings beat estimates in the first quarter of 2022. Sales jump year over year on the back of Eliquis and new products.
Lilly's experimental weight-loss drug may be a 'multibillion-dollar opportunity'
04:17pm, Friday, 29'th Apr 2022 MarketWatch
The company says tirzepatide can help people lose up to 22.5% of their body weight.
Pfizer (PFE) to Report Q1 Earnings: What's in the Cards?
03:56pm, Friday, 29'th Apr 2022 Zacks Investment Research
Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the first quarter.
Thinking of Buying BioNTech? Consider These 3 Things First
02:45pm, Friday, 29'th Apr 2022 The Motley Fool
There's trouble ahead, but a few new solutions are on the way too.
Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE
02:32pm, Friday, 29'th Apr 2022 Zacks Investment Research
Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.
AbbVie (ABBV) Tops Q1 Earnings Estimates
01:05pm, Friday, 29'th Apr 2022 Zacks Investment Research
AbbVie (ABBV) delivered earnings and revenue surprises of 0.32% and 0.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pandemic is not over yet, says Dr. Fauci, and WHO says omicron accounted for 99.7% of all cases sequenced in latest week
11:25am, Friday, 29'th Apr 2022 MarketWatch
Just hours after saying the U.S. was out of the "pandemic phase," Dr. Anthony Fauci, President Joe Biden's chief medical adviser and a leading infectious disease expert, clarified that he should have
3 Things About BioNTech That Smart Investors Know
10:18am, Friday, 29'th Apr 2022 The Motley Fool
It's unlikely to be a one-hit wonder. And that should be great for patient investors.
Want Extra Income Every Month? Invest in These 3 High-Yielding Dividend Stocks
03:30pm, Thursday, 28'th Apr 2022 The Motley Fool
Boost your portfolio's balance with these solid, income-generating investments.
Dr. Fauci clarifies ‘pandemic is not over’ yet --- U.S. is out of ‘acute’ phase
01:39pm, Thursday, 28'th Apr 2022 MarketWatch
Dr. Anthony Fauci had said the U.S. is ‘out of the pandemic phase’ earlier this week, but walked back his remarks. ‘Is the pandemic still here? Absolutely.’
How Gilead is positioning Veklury against COVID-19 antivirals like Paxlovid
01:02pm, Thursday, 28'th Apr 2022 MarketWatch
The company has an oral version of its COVID-19 drug Veklury in a clinical trial.
Can a decades-old antidepressant keep COVID-19 patients out of the hospital?
01:00pm, Thursday, 28'th Apr 2022 MarketWatch
It's one of several generic drugs that's being tested as a way to treat the virus.
Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates
11:45am, Thursday, 28'th Apr 2022 Zacks Investment Research
Merck (MRK) delivered earnings and revenue surprises of 18.23% and 5.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CDC study highlights speed with which omicron variant infected Americans, and WHO warns testing is still crucial
10:27am, Thursday, 28'th Apr 2022 MarketWatch
A report from the Centers for Disease Control and Prevention is highlighting just how many Americans have been infected with COVID-19, and how much the number increased since the arrival of the highly
